GCP
CMPX icon

GSA Capital Partners’s Compass Therapeutics CMPX Stock Holding History

GSA Capital Partners’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$154K Buy
+70,179
New +$207K 0.01% 1579
2026
Q1 		– Sell
-133,810
Closed -$719K – 1783
2025
Q4 		$719K Buy
+133,810
New +$618K 0.06% 573
2025
Q2 		– Sell
-12,187
Closed -$23K – 1787
2025
Q1 		$23K Buy
+12,187
New +$32.4K ﹤0.01% 1581
2024
Q4 		– Sell
-65,922
Closed -$121K – 1658
2024
Q3 		$121K Hold
65,922
– – 0.01% 1474
2024
Q2 		$66K Buy
+65,922
New +$96.3K ﹤0.01% 1555

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GSA Capital Partners's CMPX Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Compass Therapeutics (CMPX) in Q2 2026: 70,179 shares worth $154K. The stake represents 0.01% of the portfolio and ranks #1579 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in CMPX as recently as Q4 2025.

GSA Capital Partners first reported a position in CMPX in Q2 2024 and has held it in 5 quarters since. The position peaked at $719K in Q4 2025. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • GSA Capital Partners held 70,179 shares of Compass Therapeutics worth $154K as of Q2 2026.
  • Compass Therapeutics was a new GSA Capital Partners position in Q2 2026.
  • Compass Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1579 holding.
  • GSA Capital Partners first reported a position in Compass Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • GSA Capital Partners's Compass Therapeutics position peaked at $719K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.